Cargando…
Injectable Thermosensitive Hydrogels for a Sustained Release of Iron Nanochelators
Deferoxamine (DFO) is an FDA‐approved iron‐chelating agent which shows good therapeutic efficacy, however, its short blood half‐life presents challenges such as the need for repeated injections or continuous infusions. Considering the lifelong need of chelating agents for iron overload patients, a s...
Autores principales: | Park, Seung Hun, Kim, Richard S., Stiles, Wesley R., Jo, Minjoo, Zeng, Lingxue, Rho, Sunghoon, Baek, Yoonji, Kim, Jonghan, Kim, Moon Suk, Kang, Homan, Choi, Hak Soo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130884/ https://www.ncbi.nlm.nih.gov/pubmed/35343104 http://dx.doi.org/10.1002/advs.202200872 |
Ejemplares similares
-
Renal clearable nanochelators for iron overload therapy
por: Kang, Homan, et al.
Publicado: (2019) -
Application of
Allometric Scaling to Nanochelator
Pharmacokinetics
por: Jones, Gregory, et al.
Publicado: (2023) -
A DFX-based iron nanochelator for cancer therapy
por: Liu, Peng, et al.
Publicado: (2022) -
H-Dot Mediated Nanotherapeutics Mitigate Systemic Toxicity of Platinum-Based Anticancer Drugs
por: Yamashita, Atsushi, et al.
Publicado: (2023) -
Engineering Alendronate‐Composed Iron Nanochelator for Efficient Peritoneal Carcinomatosis Treatment
por: Zhao, Jing, et al.
Publicado: (2022)